Comparison between the EUCAST procedure and the etest for determination of the susceptibility of Candida species isolates to micafungin

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5767-5770

  Marcos Zambrano, Laura Judith ^a,b   Escribano, Pilar ^a,b,c   Rueda, Cristina ^e   Zaragoza, Óscar ^e   Bouza, Emilio ^a,b,c,d   Guinea, Jesús ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICAFUNGIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CONTROLLED STUDY; EPSILOMETER TEST; EUCAST PROCEDURE; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ARTIFACTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS;

EID: 84885909734     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01032-13     Document Type: Article

References (23)

1. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846-2856.
2. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
3. Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW. 2011. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55:3075-3083.
4. García-Effrón G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: Implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
5. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. 2012. The presence of an FKS mutation rather thanMICis an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob. Agents Chemother. 56:4862-4869.
6. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732.
7. Rodríguez-Tudela JL, Almirante B, Rodríguez-Pardo D, Laguna F, Donnelly JP, Mouton JW, Pahissa A, Cuenca-Estrella M. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604.
8. Rodríguez-Tudela JL, Martínez-Suárez JV, Dronda F, Laguna F, Chaves F, Valencia E. 1995. Correlation of in-vitro susceptibility test results with clinical response: A study of azole therapy in AIDS patients. J. Antimicrob. Chemother. 35:793-804.
9. Espinel-Ingroff A. 2000. Clinical utility of in vitro antifungal susceptibility testing. Rev. Esp. Quimioter. 13:161-166.
10. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. 2010. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 48:1592-1599.
11. Arendrup MC, García-Effrón G, Lass-Florl C, López AG, Rodríguez-Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin susceptibility testing of Candida species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and Isosensitest media. Antimicrob. Agents Chemother. 54:426-439.
12. Axner-Elings M, Botero-Kleiven S, Jensen RH, Arendrup MC. 2011. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden. J. Clin. Microbiol. 49:2516-2521.
13. Dannaoui E, Paugam A, Develoux M, Chochillon C, Matheron J, Datry A, Bouges-Michel C, Bonnal C, Dromer F, Bretagne S. 2010. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. Clin. Microbiol. Infect. 16:863-869.
14. Chryssanthou E, Cuenca-Estrella M. 2002. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-Test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
15. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST definitive document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
16. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope W. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247.
17. Durán-Valle MT, Gago S, Gómez-López A, Cuenca-Estrella M, Jiménez Díez-Canseco L, Gómez-Garces JL, Zaragoza O. 2012. Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob. Agents Chemother. 56:3417-3419.
18. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098.
19. García-Effrón G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: Implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
20. Guinea J, Peláez T, Alcalá L, Bouza E. 2007. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 57:273-276.
21. Guinea J, Peláez T, Alcalá L, Bouza E. 2006. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 56:53-55.
22. EUCAST. 2013. Micafungin and Candida spp.: Rationale for the clinical breakpoints, version 1.0, 2013. http://www.eucast.org.
23. White T, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 322. In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: A guide to methods and applications. Academic Press, San Diego, CA.